1200 Results for "

Humanization

" in MedChemExpress (MCE) Product Catalog:
Products (1200)

1200 Results for "Humanization" in MCE Product Catalog:

Cat. No.: HY-P99721
CAS No.: 1791411-57-8
Synonyms: ABT-981

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .
loading...
    loading...
Cat. No.: HY-P99740
CAS No.: 2229859-11-2

Research Areas:  

Cancer

Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
loading...
    loading...
Cat. No.: HY-P99803
CAS No.: 2145123-44-8
Synonyms: VAL-1221

Target:  

Glycosidase

Research Areas:  

Others

Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
loading...
    loading...
Cat. No.: HY-P99852
CAS No.: 1791420-09-1
Synonyms: ABT165; PR1283233

Target:  

VEGFR Notch

Research Areas:  

Cancer

Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors .
loading...
    loading...
Cat. No.: HY-P99855
CAS No.: 2254061-60-2
Synonyms: BCD-132

Target:  

CD20

Research Areas:  

Inflammation/Immunology

Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
loading...
    loading...
Cat. No.: HY-P99903
CAS No.: 2378862-90-7
Synonyms: IBI-322

Target:  

PD-1/PD-L1 CD47

Research Areas:  

Inflammation/Immunology Cancer

Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
loading...
    loading...
Cat. No.: HY-P9992
CAS No.: 2414550-93-7
Synonyms: BAY-2315497; PSMA-TTC

Target:  

PSMA Apoptosis

Research Areas:  

Cancer

Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-P99941
CAS No.: 2079108-44-2
Synonyms: INCMGA-00012; MGA-012

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
loading...
    loading...
Cat. No.: HY-P99959
CAS No.: 2379805-59-9
Synonyms: MT-3921; rH116A3

Target:  

TGF-β Receptor

Research Areas:  

Neurological Disease

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
loading...
    loading...
Cat. No.: HY-P9999
CAS No.: 2568868-35-7
Synonyms: RG6102; RO-7126209

Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar as well as plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .
loading...
    loading...
Cat. No.: HY-P99034
CAS No.: 1622075-65-3

Target:  

CD22

Research Areas:  

Cancer

Moxetumomab is a CD22-targeting monoclonal antibody that forms the component of Moxetumomab Pasudotox, a recombinant CD22-targeting immunotoxin. Moxetumomab binds to CD22 on malignant B cells and delivers the PE38 toxin domain to tumor cells. Moxetumomab can be used in research on relapsed or refractory hairy cell leukemia .
loading...
    loading...
Cat. No.: HY-P99298
CAS No.: 1278466-20-8
Synonyms: RG 7417; TNX 234; Anti-CFD Recombinant Antibody

Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
loading...
    loading...
Cat. No.: HY-P99354
CAS No.: 2329669-78-3
Synonyms: Anti-Human CTLA4xLAG3; XmAb-22841; Pavunalimab

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P99523
CAS No.: 2413453-53-7
Synonyms: AMG 199

Target:  

CD3

Research Areas:  

Cancer

Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and CD3. Vepsitamab directs CD3-positive cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .
loading...
    loading...
Cat. No.: HY-P99676
CAS No.: 2559704-24-2
Synonyms: SI-B001; BL-B01D1 Antibody

Target:  

EGFR

Research Areas:  

Cancer

Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P99679
CAS No.: 2329669-80-7

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 .
loading...
    loading...
Cat. No.: HY-P99757
CAS No.: 2278244-14-5
Synonyms: Hu3F8-BsAb

Target:  

CD3

Research Areas:  

Cancer

Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma .
loading...
    loading...
Cat. No.: HY-P99776
CAS No.: 2138442-31-4
Synonyms: XmAb-13676
Target:  

CD20 CD3

Research Areas:  

Cancer

Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
loading...
    loading...
Cat. No.: HY-P99798
CAS No.: 2251756-52-0
Synonyms: AMG 420; BI-836909

Target:  

CD3

Research Areas:  

Cancer

Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
loading...
    loading...
Cat. No.: HY-P99896
CAS No.: 2361325-98-4
Synonyms: BTRC-4017A; RG-6194

Target:  

EGFR CD3

Research Areas:  

Cancer

Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...